DAR program (AnaMar Medical/AcurePharma)

N/A

Report date: 2025/02/01 20:00:06
NME

Base Information

Drug NameDAR program (AnaMar Medical/AcurePharma)
Drug Alias Nameanti-inflammatory (AnaMar)AM-230
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionAdenosine A2a receptor agonists
TargetsAdenosine A2a receptor
Therapy Area/IndicationsOsteoarthritisArthritis, Rheumatoid
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritorySweden
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesAcure Pharma AB
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesMar-MedAcure Pharma AB
Active IndicationsN/A
Inactive IndicationsOsteoarthritisArthritis, Rheumatoid

Other Information

ATC CodeN/A
Related LinksN/A